Yavar-70A, a novel water-in-oil adjuvant: A potency study in HPV-16E7d vaccine model

Document Type : Original Article

Authors

1 Department of Cellular and Molecular Biology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

2 Poultry Viral Vaccines Research and Production Department, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization(AREEO), Karaj, Iran

3 Department of BCG Vaccine Production, Production and Research Complex, Pasteur Institute of Iran, Karaj, Iran

4 Department of Medical Vaccine, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran

5 Advanced Therapy Medicinal Product (ATMP) Department, Breast Cancer Research Center, Motamed Cancer Institute, Academic Center for Education, Culture, and Research (ACECR), Tehran, Iran

6 Recombinant Vaccine Research Center, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Objective(s): Adjuvants are some of the most important components used for vaccine formulation. In addition, the efficacy of vaccines is highly dependent on the nature of the adjuvants used. Therefore, new adjuvant formulations may help develop more potent vaccines. In the present study, the potency of an in-house and water-in-oil adjuvant (Yavar-70A) was compared with Montanide ISA 206 and Montanide ISA 266 in an HPV-16E7d vaccine model. 
Materials and Methods: Three HPV-16 E7d vaccines were formulated using three different adjuvants, Montanide ISA 206, Montanide ISA 266, and Yavar-70A, with standard protocols. Afterward, each formulation containing 10 μg of the E7d protein was administered thrice at two-week intervals to C57BL/6 mice. Serum levels of IFN-γ and IL-4 cytokines secreted from spleen cells, total IgG, and specific IgG1 and IgG2a isotypes were assessed using ELISA two weeks after the last immunization. Lymphocyte proliferative responses were also evaluated using the BrdU method.
Results: The results indicated that the vaccine formulated using the Yavar-70A adjuvant showed the highest lymphocyte proliferation responses compared with other groups and higher IFN-γ cytokine release compared with that formulated using Montanide ISA 206. However, the vaccine formulated using Montanide ISA 206 induced the highest total IgG responses compared with other groups. Importantly, the vaccine formulated using Yavar-70A decreased IL-4 secretion compared with other vaccinated groups.
Conclusion: The present study demonstrated that Yavar-70A induces cellular and humoral immunologic parameters against the HPV-16 E7d vaccine model comparable to commercialized oil-based adjuvants.

Keywords

Main Subjects

References

1. Kayser V, Ramzan I. Vaccines and vaccination: History and emerging issues. Hum Vaccin  Immunother 2021;17:5255-5268.
2. Conti AA. Vaccination through time: From the first smallpox vaccine to current vaccination campaigns against the COVID-19 pandemic. Acta Biomed 2021;92:e2021453.
3. Vetter V, Denizer G, Friedland LR, Krishnan J, Shapiro M. Understanding modern-day vaccines: what you need to know. Ann Med 2018;50:110-120.
4. Shi S, Zhu H, Xia X, Liang Z, Ma X, Sun B. Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity. Vaccine 2019;37:3167-3178.
5. Kalanaky S, Fakharzadeh S, Karimi P, Hafizi M, Jamaati H, Hassanzadeh SM, et al. Nanoadjuvants produced by advanced nanochelating technology in the inactivated-severe acute respiratory syndrome coronavirus-2 vaccine formulation: preliminary results on cytokines and IgG responses. Viral Immunol 2023;36:409-423.
6. Asefi N, Pakzad P, Khorasani A, Taghizadeh M, Amirkhani Z, Yazdi MH, et al. Ascorbic acid and α-tocopherol in the inactivated SARS-CoV-2 vaccine formulation: Induction of the Th1 pattern in aged mice. Viral Immunol 2024;37:355-370.
7.    Zhao T, Cai Y, Jiang Y, He X, Wei Y, Yu Y, et al. Vaccine adjuvants: Mechanisms and platforms. Signal Transduct Target Ther 2023;8:283-306.
8.    Kelleci K, Allahverdiyev A, Bağirova M, Ihlamur M, Abamor EŞ. Particulate and non-particle adjuvants in Leishmaniasis vaccine designs: A review. J Vector Borne Dis 2023;60:125-141.
9.    Sandbulte MR, Spickler AR, Zaabel PK, Roth JA. Optimal use of vaccines for control of influenza A virus in swine. Vaccines (Basel) 2015;3:22-73.
10.    Burakova Y, Madera R, McVey S, Schlup JR, Shi J. Adjuvants for animal vaccines. Viral Immunol 2018;31:11-22.
11.    Slepenkin A, Pal S, Rasley A, Coleman MA, de la Maza LM. Safety and efficacy of Chlamydia muridarum vaccines adjuvanted with CpG-1826 and four concentrations of Montanide-ISA-720-VG. NPJ Vaccines 2024;9:104-113.
12.    Savoji MA, Haghighat S, Mirzaee M, Golkaran B, Mirzaee R, Esfandiari B, et al. Formulation of HBs antigen in Montanide ISA266 shows superiority to commercial HBsAg vaccine in the induction of humoral immune responses. Gastroenterol Hepatol Bed Bench 2019;12:292-300.
13.    Aslam B, Hussain I, Mahmood MS, Khan A. Preparation and evaluation of Montanide ISA 206 adjuvanted bacterin of Borrelia anserina in laying chickens. J App Poultry Res 2013;22:196-203.
14.    Waghmare A, Salvi N, Deopurkar R, Shenoy P, Sonpetkar J. Evaluation of health status of horses immunized with snake venom and Montanide adjuvants, IMS 3012 (nanoparticle), ISA 206 and ISA 35 (emulsion based) during polyvalent snake antivenom production: Hematological and biochemical assessment. Toxicon 2014;82:83-92.
15.    Savoji MA, Haghighat S, Mirzaee M, Golkaran B, Mirzaee R, Esfandiari B, et al. Formulation of HBs antigen in Montanide ISA266 shows superiority to commercial HBsAg vaccine in the induction of humoral immune responses. Gastroenterol Hepatol Bed Bench 2019;12:292-300.
16.    Yasaghi M, Mahdavi M. Potentiation of human papilloma vaccine candidate using naloxone/alum mixture as an adjuvant: increasing immunogenicity of HPV-16E7d vaccine. Iran J Basic Med Sci 2016;19:1003-1009.
17.    Matić Z, Šantak M. Current view on novel vaccine technologies to combat human infectious diseases. Appl Microbiol Biotechnol 2022;106:25-56.
18.    Nooraei S, Sarkar Lotfabadi A, Akbarzadehmoallemkolaei M, Rezaei N. Immunogenicity of different types of adjuvants and nano-adjuvants in veterinary vaccines: a comprehensive review. Vaccines 2023;11:453-472.
19.    Ren J, Yang L, Xu H, Zhang Y, Wan M, Liu G, et al. CpG oligodeoxynucleotide and Montanide ISA 206 adjuvant combination augments the immune responses of a recombinant FMDV vaccine in cattle. Vaccine 2011;29:7960-7965.
20.    Savoji MA, Sereshgi MMA, Ghahari SMM, Asgarhalvaei F, Mahdavi M. Formulation of HBsAg in Montanide ISA 51VG adjuvant: Immunogenicity study and monitoring long-lived humoral immune responses. Int Immunopharmacol 2021;96:107599.
21.    Mahdavi M, Ebtekar M, Azadmanesh K, Khorramkhorshid HR, Rahbarizadeh F, Yazdi MH, et al. HIV-1 Gag p24-Nef fusion peptide induces cellular and humoral immune response in a mouse model. Acta Virol 2010;54:131-136.
22.    Hekmat S, Sadat SM, Aslani MM, Mahdavi M, Bolhassani A, Halvaee FA, et al. Truncated core/NS3 fusion protein of HCV adjuvanted with outer membrane vesicles of Neisseria meningitidis serogroup B: Potent inducer of the murine immune system. Iran Biomed J 2019;23:235-245.
23.    Kak G, Raza M, Tiwari BK. Interferon-gamma (IFN-γ): Exploring its implications in infectious diseases. Biomol Concepts 2018;9:64-79.
24.    Haghighi M, Khorasani A, Karimi P, Keshavarz R, Mahdavi M. Different formulations of inactivated SARS-CoV-2 vaccine candidates in human compatible adjuvants: Potency studies in mice showed different platforms of immune responses. Viral Immunol 2022;35:663-672.
25.    Baxter VK, Griffin DE. Interferon-gamma modulation of the local T cell response to alphavirus encephalomyelitis. Viruses 2020;12:113-137.
26.    Cortes‐Selva D, Ready A, Gibbs L, Rajwa B, Fairfax KC. IL‐4 promotes stromal cell expansion and is critical for development of a type‐2, but not a type 1 immune response. Eur J Immunol 2019;49:428-442.
27.    Alipour S, Mahdavi A. Boosting Tat DNA vaccine with Tat protein stimulates strong cellular and humoral immune responses in mice. Biotechnol Lett 2020;42:505-517.
28.    Zhu X, Zhu J. CD4 T helper cell subsets and related human immunological disorders. Int J Mol Sci 2020;21:8011-8036.
29.    Lin X, Yang Y, Li S, Li Z, Sheng Y, Su Z, et al. Oil-in-ionic liquid nanoemulsion-based adjuvant simultaneously enhances the stability and immune responses of inactivated foot-and-mouth disease virus. Int J Pharm 2022;625:122083.
 
Iranian Journal of Basic Medical Sciences
Volume 28, Issue 2
February 2025
Pages 224-229

Files

Share

How to cite

Statistics